Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Vaccine Application Extends Life of Metastatic Prostate Cancer Patients

By BiotechDaily International staff writers
Posted on 24 Feb 2010
Print article
In a newly published clinical trial, patients with metastatic prostate cancer who received a vaccine of harmless poxviruses engineered to trigger an immune system attack on prostate tumor cells lived considerably longer than patients who received a placebo vaccine.

The study's findings were published by the Journal of Clinical Oncology on its website in January 2010, and scheduled for later print publication. The randomized phase II study was performed by researchers from the Dana-Farber Cancer Institute (Boston, MA, USA) and affiliated organizations. The study involved the PROSTVAC-VF vaccine, a combination of two weakened poxviruses that have been genetically programmed to produce slightly irregular versions of prostate specific antigen (PSA)--a protein on the surface of prostate cells that is abnormal in many prostate cancers--and three costimulatory molecules that spur the immune system to a more vigorous attack on tumor cells.

The double-blinded trial included 125 patients with metastatic prostate cancer who did not respond to standard, hormone-lowering therapy. Eighty-two of the participants received the vaccine, produced by BN ImmunoTherapeutics, Inc. (Mountain View, CA, USA), and 40 received a placebo.

At the three-year point after the study, 30% of the PROSTVAC-VF patients were alive, versus 17% of the control group. The median survival of the vaccine group was 24.5 months, compared to 16 months for the control group, an 8.5-month increase.

Patients tolerated the vaccine well; only a small number experienced side effects such as fatigue, fevers, and nausea. "Although this study is relatively small, it offers encouraging evidence of a clinically meaningful benefit from this vaccine approach,” said lead investigator and lead author Philip Kantoff, M.D., of Dana-Farber, who helped design the trial.

Investigators are now planning a phase III trial that will enroll about 600 patients to evaluate further the vaccine's effectiveness.

Related Links:

Dana-Farber Cancer Institute
BN ImmunoTherapeutics



Print article

Channels

Drug Discovery

view channel
Image: A scanning electron microscope (SEM) image of methicillin-resistant Staphylococcus aureus bacteria (Photo courtesy of the CDC).

Drug Combination Cures MRSA Infection While Preventing Development of Resistance

Treatment with a combination comprising the well-known antibiotic cefdinir and the experimental drug TXA709 cured mice of drug-resistant staphylococcal infections while reducing the development of resistance.... Read more

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.